Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations
'Tracy is a seasoned executive with the strategic mindset and investor acumen needed as Fortrea enters its next chapter,' said McConnell. 'She brings not only deep capital markets expertise but also integrity, insight and a strong track record of supporting strategic transformation and growth. We're excited to welcome her to the team. I also would like to express my sincere appreciation to Hima Inguva, who has led Fortrea's Investor Relations since our founding as a company. We wish her every success in her next chapter.'
Krumme brings more than three decades of investor relations and capital markets experience to Fortrea, with expertise across the CRO, life sciences and healthcare sectors. She previously served as head of investor relations at PPD, a leading CRO acquired by Thermo Fisher Scientific, where she worked alongside Fortrea's CEO Anshul Thakral; Galderma, a global dermatology company; and Nuance Communications, a provider of healthcare AI solutions acquired by Microsoft. Most recently, she was senior vice president, head of investor relations and corporate communications at Bitfarms, a global energy and compute infrastructure company. Earlier in her career, she led investor relations at Luxoft, acquired by DXC Technology, and NCR Corporation, and held roles as an equity research analyst at Sandler O'Neill & Partners and in corporate finance at Prudential Securities and Kidder, Peabody International in London.
'I'm excited to join Fortrea at such a pivotal moment in its evolution as an independent, pure-play CRO,' said Krumme. 'I look forward to working with the leadership team to articulate Fortrea's vision and value proposition to the investment community as we deliver differentiated solutions to our customers and generate long-term value for shareholders.'
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
Fortrea Contacts:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
20 minutes ago
- Globe and Mail
SelectQuote to Release Fiscal Fourth Quarter and Full Year 2025 Earnings on August 21
SelectQuote, Inc. (NYSE: SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced it will release its fourth quarter and full year 2025 financial results before market open on Thursday, August 21, 2025. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (August 21, 2025) at 8:30 am ET to discuss the results. To register for this conference call, please use this link: After registering, a confirmation will be sent via email, including dial in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website or via this link. About SelectQuote: Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote's success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care. With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select, which proactively connects consumers with a wide breadth of healthcare services supporting their needs.
CTV News
20 minutes ago
- CTV News
Warner Bros Discovery beats second-quarter revenue estimates
Warner Bros Discovery topped Wall Street estimates for quarterly revenue on Thursday, boosted by international expansion of HBO Max and blockbuster releases including U.S. top grosser 'A Minecraft Movie.' The company, which is restructuring into studio-focused Warner Bros and cable-centric Discovery Global, reported second-quarter revenue of $9.81 billion. Analysts had expected $9.76 billion, according to data compiled by LSEG. (Reporting by Harshita Mary Varghese in Bengaluru; Editing by Arun Koyyur)
National Post
20 minutes ago
- National Post
Realbotix Collaborates with Radium to Power Real-Time AI Companions On Serverless Infrastructure
Article content LAS VEGAS — Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (' Realbotix ' or the 'Company'), a leader in AI-powered humanoid robotics, is collaborating with Radium to scale its emotionally intelligent AI applications using Radium's serverless inference platform to deliver lightning-fast conversations for its next-generation robotic companions. Article content As AI companions become more integrated into everyday technology, emotional responsiveness is emerging as a key factor in user engagement and long-term adoption. Real-time, empathetic interactions are not just a user feature, they are a market advantage, and Radium's infrastructure makes that scale possible. Article content Article content The deployment addresses a critical challenge in consumer robotics: delivering realistic conversations that don't break the illusion of interaction with artificial delays. RadiumDeploy's GPU auto-scaling ensures consistent performance even during traffic spikes. Article content 'Real-time dialogue pushes infrastructure to its limits,' said Adam Hendin, CEO of Radium. 'Our platform keeps that complexity invisible so Realbotix can focus on the user experience.' Article content While Realbotix trained its language and vision models using Radium's platform, those models now live entirely on Radium's cloud for production inference, freeing the Realbotix team to focus on crafting richer AI personalities rather than managing infrastructure and inference engines. Article content 'Radium gives us the speed, reliability, and simplicity we need to serve conversational AI at scale,' said Andrew Kiguel, CEO of Realbotix. 'Radium lets our engineers focus on creating compelling personalities rather than optimizing deployments.' Article content This collaboration reflects the growing demand for infrastructure that can support real-time, consumer-scale AI applications. Companies like Realbotix are bringing generative AI into interactive, user-facing products, creating an urgent need for inference platforms that offer low latency, high concurrency, and operational simplicity. Article content Radium provides developers with simple API endpoints for model deployment, delivering predictable performance, automatic elasticity, and cost-efficient scaling; essential capabilities for applications where user experience depends on immediate responsiveness. Article content About Realbotix Article content Realbotix designs and manufactures AI-powered humanoid robots that improve human experiences through connection, companionship and intelligent interaction. Article content Manufactured in the United States, Realbotix specializes in realistic, customizable robots built for entertainment, customer service, and personal well-being. Our patented AI and robotics technologies enable lifelike expression, motion, and social engagement, making us a category leader in the rapidly evolving field of human-centric robotics. Article content Article content Article content About Radium Article content Radium's platform provides the complete infrastructure stack for building, deploying, and serving AI models at scale. Its proprietary technology offers a significant reduction in training time and delivers class-leading inference performance in the AI cloud market. The platform is easy to use, with foundational technology that accelerates training processes while maintaining exceptional performance standards. Article content For more information visit Forward-Looking Statements This news release includes certain forward-looking statements as well as management's objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as 'may', 'will', 'plan', 'expect', 'anticipate', 'estimate', 'intend' and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, as described in more detail in our securities filings available at Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Article content Article content Article content Article content Article content Contacts Article content Article content Article content
